Contoura With Phorcides Compared to Wavefront Optimized LASIK
Recruiting
Comparison of Visual Acuity and Quality of Life Following Contoura With Phorcides Compared to WaveLight Wavefront Optimized LASIK
Who can join
Ages 21 to 38 · All sexes
Full eligibility criteria
Inclusion Criteria: * Patients at least age 21 years of age undergoing LASIK eye surgery * Willing and able to comprehend informed consent and complete 1 month post-op visit * Potential postoperative BCDVA of 20/20 or better in each eye based on Investigator's medical opinion * Candidates for Contoura with Phorcides (Myopic, astigmatism \<3.0D) * Both eyes targeted for plano * Pre-operative total corneal Pachymetry 490um or above * Stable refractive error \<0.50D change in preceding year * Good general and ocular health * Pre-operative exam completed within three months of surgery * SCL discontinued 3 days prior to pre-op exam and the procedure * Pachymetry above 490 with residual greater than 270um * Candidates who, as determined by the investigator, can safely undergo LASIK Exclusion Criteria: * Patients under 21 years of age * Concomitant ocular condition which would limit the BCVA at the discretion of the surgeon * Patients with usual relative and absolute contraindications for LASIK surgery (Patients with severe dry eye, recurrent corneal erosion, uncontrolled Glaucoma, collagen vascular disorders, keratoconus or signs of keratoconus, uncontrolled Diabetes, Herpes) * Pachymetry below 490 * Autoimmune or immunodeficiency diseases * Pregnant or nursing women * Patients with signs of inability to understand consent for study and procedure planned * Patients with history of previous ocular surgery * Patients with strabismus or amblyopia * Patients that have a BCDVA of 20/25 or worse in either eye
About the study
Comparing post-operative visual acuity and patient reported satisfaction between Contoura with Phorcides and WaveLight Wavefront Optimized.
What is being tested
- Contoura with Phorcides (procedure)
- WaveLight Wavefront Optimized (device)
Sponsor: Daniel Terveen · Participants: 120 · Started: Aug 15, 2022
Contact the study team
- Daniel Terveen, MD · Phone: 605-645-7999
- Elise Meide, M.S. · Phone: 605-645-0444
Official record on ClinicalTrials.gov — NCT05486546
Locations in the U.S.
| Montana | Vance Thompson Vison, Bozeman |
| Nebraska | Vance Thompson Vision, Omaha |
| North Dakota | Vance Thompson Vision, Fargo |
| South Dakota | Vance Thompson Vision, Sioux Falls |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.